In the case of non-small cell lung carcinoma (NSCLC), the presence of defined mutations in the EGFR kinase domain [3, 4], known as sensitizing mutations, substantially increases the response to treatment with the EGFR-specific small molecule inhibitors erlotinib and gefitinib [5–7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.